HIGH

Zydus Pharmaceuticals Recalls Icosapent Ethyl Capsules Over Subpotency

Zydus Pharmaceuticals recalled 22,896 bottles of Icosapent Ethyl capsules on December 30, 2025. The recall stems from leakage and oxidation that may reduce the drug's effectiveness. Consumers should stop using the product immediately and seek guidance from healthcare providers.

Quick Facts at a Glance

Recall Date
December 30, 2025
Hazard Level
HIGH
Brand
Zydus Pharmaceuticals
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Subpotent Drug: Due oxidation caused by leakage of the contents of the Icosapent Ethyl 1g capsules. Use of the affected product may lead to inconsistent therapeutic effects and an increase in potential gastrointestinal side effects in some patients.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Icosapent Ethyl capsules are a prescription medication used to lower triglyceride levels in patients at risk for cardiovascular disease. These capsules are typically prescribed to improve overall heart health and are taken as directed by healthcare providers.

Why This Is Dangerous

The capsules may lose potency due to leakage, leading to inconsistent therapeutic effects. Patients may not receive the intended benefits, and some may experience increased gastrointestinal side effects due to the degradation of the drug.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers may face health risks due to the potential ineffectiveness of the medication. This could lead to increased triglyceride levels and related health issues, making prompt action necessary.

Practical Guidance

How to identify if yours is affected

  1. Check the lot number on your bottle against the recalled lot numbers: S2520304, S2520333, S2540186.
  2. Verify the expiration dates: February 28, 2027, and April 30, 2027.
  3. Contact your pharmacy or Zydus Pharmaceuticals if you are unsure about your product.

Where to find product info

The lot number and expiration date can typically be found on the label of the bottle or packaging.

What timeline to expect

Expect a refund or resolution within 4-6 weeks after contacting Zydus Pharmaceuticals.

If the manufacturer is unresponsive

  • Follow up with Zydus Pharmaceuticals if you do not receive a response within a week.
  • Consider filing a complaint with the FDA if the company remains unresponsive.

How to prevent similar issues

  • Always check for recalls before using prescription medications.
  • Consult with your healthcare provider about alternative medications if you are affected by this recall.
  • Be aware of signs of degradation in medication packaging, such as unusual leaks or discoloration.

Documentation advice

Keep a record of any communications you have regarding the recall, including emails, letters, and phone call notes.

Product Details

The recall involves Icosapent Ethyl capsules, 1 gram, in 120-count bottles. The affected lot numbers include S2520304, S2520333, and S2540186, with expiration dates of February 28, 2027, and April 30, 2027. These products were manufactured by Softgel Healthcare Pvt. Ltd. in India.

Key Facts

  • Recall date: December 30, 2025
  • Distributed by: Zydus Pharmaceuticals (USA) Inc.
  • NDC: 70710-1592-07
  • Quantity recalled: 22,896 bottles
  • Manufactured in India

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
7/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Lot # S2520304
S2520333
Exp 2/28/2027
S2540186
Exp 4/30/2027
Affected States
ALL
Report Date
January 28, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more